key: cord-0066686-8k02b9g1 authors: Diongue, Khadim; Diallo, Mamadou Alpha; Seck, Mame Cheikh; Ndiaye, Mouhamadou; Badiane, Aida Sadikh; Ndiaye, Daouda title: The evidence for unavailability of systemic antifungals in Senegal date: 2021-08-09 journal: Ther Adv Infect Dis DOI: 10.1177/20499361211036594 sha: 49b728b38ea5674e6ac3533d86f9ab5999c55368 doc_id: 66686 cord_uid: 8k02b9g1 nan The frequency of invasive fungal diseases (IFDs) continues to increase, producing significant morbidity and mortality in parallel with advances in medical care that tend to weaken host defense mechanisms. 1, 2 Unfortunately, the current episode of coronavirus 2019 (COVID-19) has just exposed the deficiencies of our health systems, particularly in Africa. Even though the African region was the least affected by this pandemic, the few serious cases confronted constituted a real challenge due to a lack of infrastructure and means of care. The health systems in Africa are generally fragile and are not prepared to face such epidemics. The number of qualified human resources, the availability of biomedical materials and drugs are the challenges of African countries. 3 Globally, we are witnessing the emergence of pathologies requiring prolonged treatment during which patients receive broad-spectrum antibiotic therapy and are subject to numerous invasive procedures such as the presence of a central venous catheter, which may promote direct vascular access of Candida spp. following previous colonization. 4 These conditions, even temporary, can provoke the development of IFDs. This is the case with AIDS, cancers, especially blood cancers such as leukemia, hemodialysis, etc. Indeed, fungi are responsible for more than a billion cutaneous infections, more than 100 million mucous infections, 10 million serious allergies, and more than a million deaths each year. Global mortality due to fungal diseases (FDs) is higher than for malaria and breast cancer and is comparable to that from tuberculosis (TB) and HIV. These statistics show that FDs are a threat to human health and a major burden on healthcare budgets around the world. 5 Antifungals -molecules used to treat FDs -fall into two categories. On the one hand, local antifungals or topicals are not absorbed orally, they are used locally for a local effect. On the other hand, systemic antifungals are absorbed orally or administered intravenously; they diffuse in the viscera. 6 The latter group is divided into four classes: polyenes (amphotericin), azoles (fluconazole, itraconazole, voriconazole, posaconazole, isavuconazole), echinocandins (caspofungin, anidulafungin, micafungin), and nucleoside analogs such as 5-fluorocytosine (flucytosine). 7, 8 For pharmacokinetic reasons, molecules such as griseofulvin (naturally occurring extract from Penicillium griseofulvum) or terbinafine (allylamines) are absorbed orally but are concentrated exclusively in the superficial skin layers. Thus, they are compared to topicals concerning therapeutic indications. 6 Senegal is hardly an exception to this situation. Our country is also going through a socioeconomic transition responsible for a medical transition. Risk factors for IFDs are present across the country; for example, the number of patients with HIV was estimated at 42,000 in 2019 with 63% on antiretroviral treatment. 9 Other risk factors identified include leukemia, diabetes, asthma, and TB [9] [10] [11] [12] (Table 1) . Thus, the Senegalese specialist will be increasingly confronted with the diagnosis and management of FDs. If the current antifungal arsenal in Senegal has molecules efficient for treating superficial FDs with molecules such as griseofulvin or fluconazole, 13 many deep fungal diseases (DFDs) do not yet benefit from effective treatment with the absence or unavailability of antifungal drugs. 14, 15 Consequently, based on data from Aristide Le Dantec and Fann University Hospital Centers in Dakar, which are the only public health establishments with a medical mycology laboratory, the objective of this communication was to update the table of the main FDs diagnosed in Senegal and the antifungals available for their therapeutic management to draw attention to these infections increasingly diagnosed with the emergence of new opportunistic fungi. Over the past two decades, the main publications mostly found on Pubmed and Google Scholar databases with 'mycoses' and 'Senegal' as keywords show the principal part of the epidemiology of FDs diagnosed in Dakar (capital of Senegal) which concentrates the only medical mycology laboratories in the country. These publications (Table 2 ) mainly concern superficial FDs such as tinea capitis, [16] [17] [18] onychomycoses, [19] [20] [21] intertrigos, 22-24 among others, [25] [26] [27] [28] [29] [30] [31] and subcutaneous FDs such as mycetomas [32] [33] [34] [35] and exceptionally chromomycosis. 36 These superficial and subcutaneous FDs generally have an arsenal of antifungals that permit their management even if the latter treatment sometimes remains probabilistic. 37 For DFDs, the reported publications essentially concern histoplasmosis, 38,39 especially the African form often treated with disappointment, 15 and cryptococcosis with which alternative treatment regimens have been adopted with a success rate estimated at 36.7%. 40 Rare cases of pneumocystosis 41 and aspergillosis/aspergilloma have been reported, treated by surgery without any adjunction of antifungal for the aspergilloses' management, possibly due to antifungals unavailability. [42] [43] [44] This relatively low frequency of DFDs aside from cryptococcosis, 45, 46 which represented more than half (50.8%) of the requests for diagnosis of DFDs in Fann University Hospital, 47 would be mostly related to the weakness of the technical material and use of little sensitive biological tools of diagnosis. 41 These diagnostic problems are corroborated by data from the infectious diseases department of this same institution. Indeed, according to a study carried out in this latter service on non-TB lower respiratory infections (LRI) in HIV patients between 2011 and 2015, out of the 255 patients with non-TB LRI, only three fungal etiologies (1.2%) were noted, including two cases due to unidentified yeasts. In addition, in 70.9% of cases, no etiology was found, which therefore motivated the administration of an antifungal (fluconazole) in 57.6% of patients and cotrimoxazole at a curative dose in 30.9% 48 for preventing a probable pneumocystosis. These probabilistic treatments could contribute to the emergence of antimicrobial resistance given the already unavailability of antifungals. All the more so since, out of the 477 requests for the diagnosis of pneumocystosis received between 2005 and 2017 by the parasitology and mycology laboratory in Fann University Hospital, which hosts one of the few pneumology services in the public in Senegal, only 28 were positive corresponding to a hospital prevalence of 5.9%. 47 Furthermore, in our microbiology laboratories in general and medical mycology laboratories in particular, the diagnosis is essentially based on conventional methods including direct microscopic examination and culture on Sabouraud dextrose agar (SDA), with identification of causative agents predominantly based on macroscopic and microscopic morphological characteristics. The only one matrix-associated laser desorption and Table 1 . Risk factors of invasive fungal diseases in Senegal, prevalence, and incidence of the principal underlying diseases. [9] [10] [11] [12] . ionization time of flight mass spectrometry (MALDI-TOF MS)-based device accessible in the country is installed in 'Hôpital Principal' in Dakar, a hospital that does not specially perform mycological analyses, and accordingly, the database of this device does not include fungal species aside from the classic species of the genus Candida. The same is true for most private laboratories that have the Vitek 2 instrument. Another problem that could explain this situation is the unequal distribution of the health system in Senegal. Indeed, as human resources, most of the infrastructure of the health system is based in Dakar. Except for health huts and level 2 hospitals, Dakar is the region with the best health infrastructure. Senegal has 11 level-3 hospitals, among them, 10 are in the Dakar region and the other in Touba, Diourbel region (185 km from Dakar). 49 Therefore, to compensate, populaces in remote areas devote themselves to traditional medicine by attending traditional healers which sometimes delays treatment and leads to disastrous consequences. This is the case with patients with mycetoma. These patients are often received at an advanced stage of the disease with surgical excisions or amputation as the only treatment options. This is evidenced by the recent case of pulmonary metastasis of a knee mycetoma observed in Aristide Le Dantec University Hospital. The patient wasted a lot of time having their lesions treated by traditional practitioners at least for 10 years. 50 The low knowledge of IFDs among physicians may also explain this situation. In fact, according to our mycological laboratory experience, almost only dermatologists systematically send requests for mycological analyzes. Apart from them, the other specialists only resort to the mycology laboratory in no-way-out-situations when they have explored all other possibilities. Moreover, a crosssectional multicenter survey across seven tertiary hospitals in five geopolitical zones of Nigeria between June 2013 and March 2015 showed that only 0.002% (2/1046) of the respondents had a good level of awareness of IFDs. 51 Table 2 . Principal fungal diseases (mycoses) diagnosed in Senegal. Common Superficial Tinea capitis Ndiaye et al., 16 Kane et al., 17 Ndiaye et al. 18 Onychomycoses Seck et al., 19 Sylla et al., 20 Diongue et al. 21 Intertrigos Diongue et al., 22 Ndiaye et al., 23 Diongue et al. 24 Pityriasis versicolor, otitis and vulvovaginal candidiasis Dioussé et al., 25 Diongue et al., 26 Dieng et al., 27 Sylla et al. 28 Subcutaneous Mycetomas Ndiaye et al., 32 Dieng et al., 33 Sow et al., 34 Badiane et al., 35 Diatta et al. 37 Deep Cryptococcosis Sow et al., 40 Diallo Mbaye et al., 45 Manga et al. 46 Pneumocystosis Dieng et al. 41 Uncommon Superficial keratitis, endodontic candidiasis Ndoye et al., 29 Diongue et al., 30 Ndiaye et al. 31 Subcutaneous Chromomycosis Develoux et al. 36 Deep Histoplasmosis Ndiaye et al., 14 Diadie et al., 15 Diongue et al., 38 Dieng et al. 39 Aspergillosis Ndiaye et al., 42 Ade et al., 43 According to the distribution circuit of drugs in Senegal (Figure 1 ), 13 populations can only obtain drugs from two sources: health organizations and pharmacies. This distribution circuit is also applicable to hospital pharmacies according to an investigation carried out in Aristide Le Dantec University Hospital and Fann University Hospital on the flow of antifungals situation. Indeed, these hospital pharmacies can only obtain antifungals through the national supply pharmacy (NSP). Consequently, in the case of medical prescription of non-available antifungals in health facilities, patients should look for them in pharmacies that may have them in situ or order them via their commercial connections, connections that are only within the reach of a small group. By compiling the list of essential drugs in Senegal and the list of antifungals available from two of the four drugs wholesaler distributions to pharmacies, antifungals available in Senegal are summarized in Table 3 with their indications. 53 Thus, the remark is that only fluconazole is available as a systemic antifungal in Senegal, whereas this molecule has no activity on a large number of the fungi responsible for DFDs encountered in Senegal. First, fluconazole does not work against infections caused by Aspergillus spp. 54 Then, regarding candidiasis, while Candida albicans is usually sensitive to antifungals comprising fluconazole, this is not the same for other non-albicans species. Candida krusei exhibits natural resistance to fluconazole while Candida glabrata has variable or even dose-dependent azole susceptibility. 55 As in general, our laboratories only performed the germ tub test to distinguish C. albicans from non-albicans species, 56 the probabilistic use of fluconazole could lead to therapeutic failure or selection of resistant strains, as already seen in immunosuppressed patients on chronic fluconazole prophylaxis. 57 So, our country is lagging far behind, particularly at a time when the country is witnessing the emergence of pathologies such as renal failure and cancer, but also the development of the means implemented for their management such as hemodialysis centers or chemotherapy centers and even the establishment of a national organ donation committee responsible for regulating kidney transplantation. 58 In our sub-region for example, four antifungal agents for IFDs (amphotericin B, fluconazole, itraconazole and voriconazole) were licensed in Nigeria. 51 Even better in north Africa, all classes of systemic antifungals (amphotericin B Adapted from the National Essentials Drug, 2018 version. 13 Black arrows represent regulation and control, blue arrows are for distributions and orange arrows are for delivery. for polyenes, fluconazole, itraconazole, voriconazole for azoles, caspofungin, micafungin, anidulafungin for echinocandins and flucytosine for nucleoside analogs) are available in Morocco (http://dmp.sante.gov.ma/) and Tunisia (http:// www.dpm.tn/). It appears from this analysis that FDs are regularly diagnosed in Senegal. However, DFDs are maybe underestimated probably related to the weakness of the technical platform and consequently the use of insensitive biological diagnostic tools. Also, the few cases of DFDs diagnosed do not benefit from antifungal molecules for specific effective treatment. Therefore, the most recent technical approaches and the most effective therapies must be adopted for rapid diagnosis and better management of DFDs. Likewise, molecular identification techniques should be added to conventional methods. For antifungal availability, a network based on the directory of African pharmacy and drug directorates must be set up and run in collaboration with the national laboratory directorates for harmonization of procedures to reduce morbidity and mortality related to IFDs, especially in Africa. Once again, this will depend at all decision-making levels, on the ability to provide to relevant actors the means to know, recognize, and appropriately treat FDs, especially for DFDs. The evolving landscape of fungal diagnostics, current and emerging microbiological approaches Guidelines for the use of antifungal agents in patients with invasive fungal diseases in Taiwan COVID-19: Le système de santé des pays africains est très fragile et n'est pas prêt à faire face à cette pandémie Émergence de nouveaux champignons pathogènes en médecine: revue générale Medical mycology and fungal immunology: new research perspectives addressing a major world health challenge Collège des Universitaires de Maladies Infectieuses et Tropicales (CMIT). ePILLY trop 2016: Maladies infectieuses tropicales. Edition web mise à jour Août Antifungal drugs: what brings the future? Antifungal agents UNAIDS data National strategic plan to reduce human rights -related barriers to HIV, TB and malaria services: Senegal 2021-2025 World Health Organization (WHO) The Global Cancer Observatory (Globocan) Ministère de la Santé et de l'action Sociale. Liste nationale de médicaments et produits essentiels du Sénégal. Arrêté ministériel N° 016917/MSAS/ DGS/DPM Histoplasmose disséminée à Histoplasma capsulatum var. duboisii au Sénégal. À propos d'un cas chez un patient VIH positif Histoplasmose multifocale à Histoplasma capsulatum var. duboisii chez un Sénégalais de 22 ans sans immunodépression prouvée Profil épidémiologique des teignes du cuir chevelu à Dakar (Sénégal) Tinea in Senegal: an epidemiologic study Teignes du cuir chevelu diagnostiquées au Sénégal Profil mycologique des onychomycoses à Dakar (Sénégal) Epidemiological and mycological aspects of onychomycosis in Dakar (Senegal) Onychomycosis caused by Fusarium spp. in Dakar, Senegal: epidemiological, clinical, and mycological study Fungal interdigital tinea pedis in Dakar (Senegal) Etiologie des intertrigos chez l'adulte: étude prospective de 103 cas Les intertrigos interorteils impliquant Fusarium spp. à Dakar (Sénégal) Pityriasis versicolor chez des nourrissons: aspect clinique inhabituel et rôle de la dépigmentation cosmétique par des corticoïdes chez la mère MALDI-TOF MS identification of Malassezia species isolated from patients with pityriasis versicolor at the Seafarers' Medical Service in Dakar, Senegal Otomycosis at Fann Hospital in Dakar (Senegal): prevalence and mycological study Candidoses vulvo-vaginales au laboratoire de Parasitologie-Mycologie du centre hospitalier universitaire de Fann, Dakar (Sénégal) Problème diagnostique et thérapeutique de la kératite mycosique en zone intertropicale. Intérêt de l'usage local de la polividone iodée Kératomycose à Fusarium oxysporum traitée par l'association de la povidone iodée en collyre et du fluconazole per os Recherche de levures dans les primo-infections endodontiques et étude de leur sensibilité à une désinfection à l'hypochlorite de sodium à 2.5% Mycétomes diagnostiqués au Sénégal de Mycetoma: 130 cases Mycetoma epidemiology, diagnosis management, and outcome in three hospital centres in Senegal from Geographical distribution of mycetoma cases in Senegal over a period of 18 years Chromomycose à Exophiala spinifera en Afrique sahélienne Un mycétome fongique tumoral dorsal: intérêt de la chirurgie large associée à la terbinafine Champignons non dermatophytiques et non candidosiques isolés au CHU Le Dantec de Dakar en 2014: étude épidémiologique, clinique et mycologique Amplification of blood smear DNA to confirm disseminated histoplasmosis Cryptococcal meningitis in Senegal: epidemiology, laboratory findings, therapeutic and outcome of cases diagnosed from Diagnostic biologique de la pneumonie à Pneumocystis au centre hospitalier universitaire de Fann, Dakar, Sénégal Aspergillose sinusienne invasive pseudotumorale: à propos de deux cas Aspects épidémiologiques, cliniques, thérapeutiques et évolutifs de l'aspergillome pulmonaire à Dakar Résultats du traitement chirurgical de l'aspergillome pulmonaire à Dakar Cryptococcose neuro-méningée: mortalité et facteurs associés au décès chez les patients hospitalisés au service des maladies infectieuses du CHNU de Fann Prevalence and factors associated with positive cryptococcal antigenemia among HIV infected adult hospitalized in Senegal Profil épidémiologique et mycologique des infections fongiques profondes diagnostiquées au CHNU de Fann de diagnostic et traitement des infections respiratoires basses non tuberculeuses chez les PVVIH au service des maladies infectieuses du Centre national hospitalier universitaire (CHNU) de Fann Situation économique et sociale du Sénégal en Métastase pulmonaire d'un mycétome du genou au Sénégal Evaluation of knowledge and awareness of invasive fungal infections amongst resident doctors in Nigeria Antifongiques et mycoses superficielles Centers for Diseases Control and Prevention (CDC) Species spectrum and antifungal susceptibility profile of K Diongue vaginal isolates of Candida in Kuwait MALDI-TOF MS identification and antifungal susceptibility of Candida strains isolated from vulvovaginal candidiasis by the AST-YS08 ® Card with Vitek 2 ® in Dakar, Senegal Clinical mycology Décret de la loi N° 2015-22 du 08 décembre 2015 relative au don, prélèvement et à la transplantation d'organes et aux greffes de tissus humains Visit SAGE journals online journals.sagepub.com/ home/tai The authors are grateful to the following drug distribution companies: SODIPHARM and DUOPHARM in Senegal for providing them with their lists of marketed drugs. They are also thankful to hospital pharmacies staff in Aristide Le Dantec University Hospital and Fann University Hospital. Conception, design of the study, and drafting the article: Khadim Diongue; reviewing the article: Mamadou A Diallo, Mame C Seck, Mouhamadou Ndiaye, Aida S Badiane, Daouda Ndiaye D; final approval of the version to be submitted: all authors. The authors declare that there is no conflict of interest. The authors received no financial support for the research, authorship, and/or publication of this article. Our study did not require an ethical board approval because it did not contain human or animal trials. Diongue K https://orcid.org/0000-0002-7033-1169 Data availability Data used to support the findings of this study are included within the article.